BioMedLib Search Engine [ goto HOMEPAGE ]

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Combination of all-trans-retinoic acid and gemtuzumab ozogamicin in an elderly patient with acute promyelocytic leukemia and severe cardiac failure.

All-trans-retinoic acid (ATRA) combined with anthracyclines is currently the standard treatment for acute promyelocytic leukemia (APL).

The patient obtained a complete hematological and molecular remission.

No adverse events were observed in every phase of treatment and the patient is still in complete continuous hematological and molecular remission 29 months from diagnosis.

[MeSH-major] Aminoglycosides / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Heart Failure / complications. Leukemia, Promyelocytic, Acute / complications. Leukemia, Promyelocytic, Acute / drug therapy. Tretinoin / administration & dosage

[MeSH-minor] Aged. Antibodies, Monoclonal, Humanized. Drug Therapy, Combination. Humans. Male. Remission Induction. Severity of Illness Index

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

MedlinePlus Health Information. consumer health - Heart Failure.

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] 2007 S. Karger AG, Basel

(PMID = 17167240.001).

[ISSN] 1421-9662

[Journal-full-title] Acta haematologica

[ISO-abbreviation] Acta Haematol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Switzerland

[Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / gemtuzumab; 5688UTC01R / Tretinoin

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Gangrenous cheilitis associated with all-trans retinoic acid therapy for acute promyelocytic leukemia.

A 67-year-old Japanese woman who presented with erythema on the abdomen and pancytopenia was found to have acute promyelocytic leukemia (APL).

She achieved complete remission and the gangrenous cheilitis slowly healed over the following 8 weeks.

[MeSH-major] Antineoplastic Agents / adverse effects. Cheilitis / chemically induced. Leukemia, Promyelocytic, Acute / drug therapy. Tretinoin / adverse effects

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Lancet. 2006 Jul 8;368(9530):147-56 [16829299.001]

[Cites] Blood. 1995 May 15;85(10):2643-53 [7742522.001]

[Cites] Can Vet J. 1995 Feb;36(2):106-7 [7728725.001]

[Cites] Rinsho Ketsueki. 1998 Jan;39(1):48-52 [9492553.001]

[Cites] Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5328-35 [15044693.001]

[Cites] Br J Haematol. 1997 May;97(2):300-5 [9163592.001]

[Cites] Ann Intern Med. 1992 Aug 15;117(4):292-6 [1637024.001]

[Cites] Pediatr Dermatol. 2003 Nov-Dec;20(6):519-23 [14651574.001]

[Cites] Ann Hematol. 2002 Feb;81(2):111-4 [11907794.001]

[Cites] Intern Med. 2005 May;44(5):480-3 [15942099.001]

[Cites] Clin Sci (Lond). 2007 Jun;112(7):375-84 [17324119.001]

(PMID = 20035486.001).

[ISSN] 1865-3774

[Journal-full-title] International journal of hematology

[ISO-abbreviation] Int. J. Hematol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Japan

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Identification of atypical PML-RARA breakpoint in a patient with acute promyelocytic leukemia.

Acute promyelocytic leukemia (APL) of the M3 subtype is characterized by translocation t(15;17) that generates the PML-RARA fusion gene.

The patient responded well to treatment and is now in complete remission.

[MeSH-major] Chromosomes, Human, Pair 15 / genetics. Chromosomes, Human, Pair 17 / genetics. Exons / genetics. Leukemia, Promyelocytic, Acute / genetics. Oncogene Proteins, Fusion / genetics. Translocation, Genetic / genetics

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] 2007 S. Karger AG, Basel

(PMID = 17934255.001).

[ISSN] 1421-9662

[Journal-full-title] Acta haematologica

[ISO-abbreviation] Acta Haematol.

[Language] eng

[Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Switzerland

[Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein

   

Advertisement

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The t(5;17)/NPM-RARalpha is the second variant chromosomal translocation in acute promyelocytic leukemia (APL) to be characterized and also the second most plentiful variant translocation.

[MeSH-major] Antineoplastic Agents / therapeutic use. Arsenicals / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Leukemia, Promyelocytic, Acute / genetics. Oncogene Proteins, Fusion / genetics. Oxides / therapeutic use

[MeSH-minor] Adult. Disease-Free Survival. Female. Humans. Recurrence. Remission Induction

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Blood. 2007 Dec 1;110(12 ):4073-6 [17712046.001]

[Cites] Oncogene. 1999 Jan 28;18(4):1113-8 [10023688.001]

[Cites] Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2008 Aug;25(4):430-3 [18683144.001]

[Cites] Blood. 2009 Feb 26;113(9):1875-91 [18812465.001]

[Cites] J Clin Oncol. 2001 Sep 15;19(18):3852-60 [11559723.001]

[Cites] Blood. 2008 Mar 1;111(5):2505-15 [18299451.001]

[Cites] Best Pract Res Clin Haematol. 2003 Sep;16(3):387-408 [12935958.001]

[Cites] Blood. 2006 Apr 1;107(7):2627-32 [16352810.001]

[Cites] Leukemia. 2002 Oct;16(10):1927-32 [12357344.001]

[Cites] Int J Hematol. 2007 Oct;86(3):246-9 [17988991.001]

[Cites] Blood. 1997 May 1;89(9):3354-60 [9129042.001]

[Cites] Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3342-7 [19225113.001]

[Cites] Am J Hematol. 2002 Aug;70(4):292-9 [12210810.001]

(PMID = 20405253.001).

[ISSN] 1865-3774

[Journal-full-title] International journal of hematology

[ISO-abbreviation] Int. J. Hematol.

[Language] eng

[Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Japan

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / NPM-RARalpha protein, human; 0 / Oncogene Proteins, Fusion; 0 / Oxides; S7V92P67HO / arsenic trioxide

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Open issues on bleeding and thrombosis in acute promyelocytic leukemia.

Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia characterized by a specific genetic alteration, affecting the retinoic acid receptor-alpha (RAR-alpha), and leading to the accumulation of the promyelocytic blasts in the bone marrow and blood which is frequently associated with a life-threatening consumptive coagulopathy.

The body of biological information on APL establishes this leukemia as a unique entity that has to be promptly recognized to counteract the coagulopathy, especially in light of its striking response to treatment with all-trans retinoic acid.

In fact, the current standard for induction therapy results in extremely high antileukemic efficacy, achieving 90 to 95% complete remission rate.

However, while primary leukemia resistance has virtually disappeared as a cause of remission induction failure, death due to hemorrhage remains the major problem during the early treatment phase.

[MeSH-major] Hemorrhage / diagnosis. Hemorrhage / etiology. Leukemia, Promyelocytic, Acute / complications. Thrombosis / diagnosis. Thrombosis / etiology

[MeSH-minor] Disseminated Intravascular Coagulation / diagnosis. Disseminated Intravascular Coagulation / epidemiology. Disseminated Intravascular Coagulation / etiology. Disseminated Intravascular Coagulation / therapy. Humans

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

Genetic Alliance. consumer health - Thrombosis.

Genetics Home Reference. consumer health - acute promyelocytic leukemia.

MedlinePlus Health Information. consumer health - Bleeding.

MedlinePlus Health Information. consumer health - Blood Clots.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20434005.001).

[ISSN] 1879-2472

[Journal-full-title] Thrombosis research

[ISO-abbreviation] Thromb. Res.

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Number-of-references] 19

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Regulation of CYP26A1 expression by selective RAR and RXR agonists in human NB4 promyelocytic leukemia cells.

All-trans retinoic acid (ATRA) can induce complete remission in acute promyelocytic leukemia (APL), but resistance to this treatment develops rapidly partly due to increased ATRA metabolism.

Among the cytochrome P450s (CYPs) involved in ATRA metabolism, the ATRA-inducible cytochrome P450 26A1 (CYP26A1) is particularly active although the molecular mechanisms involved in its regulation are not well defined in the target leukemia cells.

To study CYP26A1 expression and regulation in APL cells, we used the NB4 promyelocytic leukemia cell line.

To further define CYP26A1 induction mechanisms in the NB4 leukemia cells, we used RARs and RXR selective agonists.

In conclusion, we have shown that CYP26A1 induction is not essential for the granulocytic maturation of NB4 leukemia cells, and that CYP26A1 induction requires the activation of both RARalpha and RXR in these cells.

[MeSH-major] Cytochrome P-450 Enzyme System / biosynthesis. Leukemia, Promyelocytic, Acute / enzymology. Receptors, Retinoic Acid / agonists. Retinoid X Receptors / agonists

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15896339.001).

[ISSN] 0006-2952

[Journal-full-title] Biochemical pharmacology

[ISO-abbreviation] Biochem. Pharmacol.

[Language] eng

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Receptors, Retinoic Acid; 0 / Retinoid X Receptors; 0 / retinoic acid receptor alpha; 0 / retinoic acid receptor beta; 9035-51-2 / Cytochrome P-450 Enzyme System; EC 1.14.14.1 / retinoic acid 4-hydroxylase

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Clinical observation and follow-up study on acute promyelocytic leukemia in childhood treated mainly with arsenic trioxide].

[MeSH-major] Antineoplastic Agents / therapeutic use. Arsenicals / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Oxides / therapeutic use

[MeSH-minor] Child. Child, Preschool. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Remission Induction / methods. Survival Rate. Treatment Outcome

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16083560.001).

[ISSN] 0578-1310

[Journal-full-title] Zhonghua er ke za zhi = Chinese journal of pediatrics

[ISO-abbreviation] Zhonghua Er Ke Za Zhi

[Language] chi

[Publication-type] Journal Article

[Publication-country] China

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; S7V92P67HO / arsenic trioxide

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Is cytarabine required in the treatment of acute promyelocytic leukemia?

Until the late 1980s, chemotherapy with anthracyclines and cytarabine (AraC) was the only treatment approach for acute promyelocytic leukemia (APL), as for other types of acute myeloid leukemia.

Several groups have reported high rates of complete remission and low rates of relapse with ATRA and chemotherapy using anthracyclines alone, suggesting that AraC could be avoided in the chemotherapy of APL, reducing toxicity.

[MeSH-major] Cytarabine / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy

[MeSH-minor] Adult. Anthracyclines / administration & dosage. Anthracyclines / adverse effects. Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / adverse effects. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Clinical Trials as Topic. Combined Modality Therapy. Humans. Middle Aged. Multicenter Studies as Topic. Randomized Controlled Trials as Topic. Remission Induction. Treatment Outcome. Tretinoin / administration & dosage. Tretinoin / adverse effects

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

Hazardous Substances Data Bank. CYTARABINE .

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Blood. 1995 Sep 1;86(5):1717-28 [7655004.001]

[Cites] Leukemia. 1992;6 Suppl 1:64-6 [1548938.001]

[Cites] Cancer. 1997 Dec 1;80(11 Suppl):2181-5 [9395031.001]

[Cites] Semin Hematol. 1996 Oct;33(4 Suppl 3):12-7 [8916311.001]

[Cites] Blood. 1993 Dec 1;82(11):3241-9 [8241496.001]

[Cites] Blood. 1992 Feb 1;79(3):543-53 [1732003.001]

[Cites] Leuk Lymphoma. 1991;4(4):239-48 [27463043.001]

[Cites] Br J Haematol. 1976 Aug;33(4):451-8 [188440.001]

[Cites] Cell. 1991 Aug 23;66(4):675-84 [1652369.001]

[Cites] N Engl J Med. 1991 May 16;324(20):1385-93 [1850498.001]

[Cites] Blood. 2004 Feb 15;103(4):1237-43 [14576047.001]

[Cites] Blood. 1998 Oct 15;92(8):2712-8 [9763554.001]

[Cites] Blood. 1989 Apr;73(5):1116-22 [2930837.001]

[Cites] Blood. 2010 Oct 28;116(17):3171-9 [20644121.001]

[Cites] Blood. 1988 Aug;72(2):567-72 [3165295.001]

[Cites] Leukemia. 1994;8 Suppl 2:S38-41 [7815835.001]

[Cites] Blood. 1999 Aug 15;94(4):1192-200 [10438706.001]

[Cites] Am J Med. 1984 May;76(5):827-41 [6586073.001]

[Cites] Leukemia. 2005 Feb;19(2):230-3 [15565164.001]

[Cites] J Clin Oncol. 1997 Feb;15(2):483-90 [9053469.001]

[Cites] Blood. 2002 Nov 1;100(9):3141-6 [12384411.001]

[Cites] Nouv Rev Fr Hematol. 1984;26(6):371-8 [6597407.001]

[Cites] Ann Intern Med. 1992 Aug 15;117(4):292-6 [1637024.001]

[Cites] Blood. 2000 Aug 15;96(4):1247-53 [10942364.001]

[Cites] N Engl J Med. 1997 Oct 9;337(15):1021-8 [9321529.001]

(PMID = 20425342.001).

[ISSN] 1558-822X

[Journal-full-title] Current hematologic malignancy reports

[ISO-abbreviation] Curr Hematol Malig Rep

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Anthracyclines; 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; 5688UTC01R / Tretinoin

[Number-of-references] 26

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Auto-SCT for AML in second remission: CALGB study 9620.

We studied the feasibility and efficacy of a two-step approach to Auto-SCT for patients with AML in second remission.

The most important prognostic factor was cytogenetics, with acute promyelocytic leukemia (APL) patients having a 5-year DFS of 67% compared with 16% for others.

[MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Cytarabine / therapeutic use. Etoposide / therapeutic use. Leukemia, Myeloid, Acute / therapy. Peripheral Blood Stem Cell Transplantation

[MeSH-minor] Adult. Aged. Aging. Antigens, CD34 / analysis. Combined Modality Therapy / adverse effects. Disease-Free Survival. Female. Humans. Ideal Body Weight. Infusions, Intravenous. Kaplan-Meier Estimate. Male. Middle Aged. Remission Induction. Transplantation, Autologous. Treatment Outcome. Treatment Refusal. Young Adult

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

COS Scholar Universe. author profiles.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

Hazardous Substances Data Bank. CYTARABINE .

Hazardous Substances Data Bank. ETOPOSIDE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19289999.001).

[ISSN] 1476-5365

[Journal-full-title] Bone marrow transplantation

[ISO-abbreviation] Bone Marrow Transplant.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / CA02599; United States / NCI NIH HHS / CA / CA03927; United States / NCI NIH HHS / CA / CA04457; United States / NCI NIH HHS / CA / CA07968; United States / NCI NIH HHS / CA / CA21060; United States / NCI NIH HHS / CA / CA26806; United States / NCI NIH HHS / CA / CA29165; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA31983; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA35279; United States / NCI NIH HHS / CA / CA41287; United States / NCI NIH HHS / CA / CA45808; United States / NCI NIH HHS / CA / CA47559; United States / NCI NIH HHS / CA / CA47577; United States / NCI NIH HHS / CA / CA60138; United States / NCI NIH HHS / CA / CA77406; United States / NCI NIH HHS / CA / CA77440; United States / NCI NIH HHS / CA / CA77658

[Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural

[Publication-country] England

[Chemical-registry-number] 0 / Antigens, CD34; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia.

All-trans retinoic acid (ATRA)/arsenic trioxide (ATO) combination-based therapy has benefitted newly diagnosed acute promyelocytic leukemia (APL) in short-term studies, but the long-term efficacy and safety remained unclear.

Eighty patients (94.1%) entered complete remission (CR).

[MeSH-major] Arsenicals / adverse effects. Arsenicals / therapeutic use. Leukemia, Promyelocytic, Acute / diagnosis. Leukemia, Promyelocytic, Acute / drug therapy. Oxides / adverse effects. Oxides / therapeutic use. Tretinoin / adverse effects. Tretinoin / therapeutic use

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Blood. 2008 Mar 1;111(5):2527-37 [17965322.001]

[Cites] Leuk Res. 2007 Nov;31(11):1585-7 [17416415.001]

[Cites] Proc Natl Acad Sci U S A. 2008 Mar 25;105(12):4826-31 [18344322.001]

[Cites] Nat Cell Biol. 2008 May;10(5):547-55 [18408733.001]

[Cites] Pediatr Blood Cancer. 2008 Jul;51(1):133-5 [18293388.001]

[Cites] Blood. 2008 Nov 1;112(9):3587-90 [18703707.001]

[Cites] Blood. 2007 Jan 15;109(2):740-6 [16968895.001]

[Cites] Leukemia. 2000 Aug;14(8):1371-7 [10942231.001]

[Cites] Blood. 2001 Jan 1;97(1):264-9 [11133770.001]

[Cites] Br J Haematol. 2002 Apr;117(1):130-2 [11918543.001]

[Cites] Hematol J. 2001;2(5):330-40 [11920269.001]

[Cites] Blood. 2002 Jul 1;100(1):59-66 [12070009.001]

[Cites] Eur J Haematol. 2002 May;68(5):310-3 [12144538.001]

[Cites] Blood. 2002 Dec 15;100(13):4298-302 [12393590.001]

[Cites] J Clin Oncol. 2003 Jun 15;21(12):2326-34 [12805334.001]

[Cites] Leukemia. 2003 Sep;17(9):1916-7; author reply 1918 [12970801.001]

[Cites] J Clin Oncol. 2003 Dec 15;21(24):4642-9 [14673054.001]

[Cites] Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5328-35 [15044693.001]

[Cites] Ai Zheng. 2004 Apr;23(4):430-4 [15087033.001]

[Cites] Hematol Oncol. 2004 Jun;22(2):63-71 [15468344.001]

[Cites] Blood. 1973 Apr;41(4):489-96 [4510926.001]

[Cites] Blood. 1988 Aug;72(2):567-72 [3165295.001]

[Cites] Blood. 1993 Dec 1;82(11):3241-9 [8241496.001]

[Cites] Blood. 1996 Aug 1;88(3):1052-61 [8704214.001]

[Cites] Blood. 1996 Oct 15;88(8):2826-32 [8874178.001]

[Cites] Leukemia. 1996 Dec;10(12):1911-8 [8946930.001]

[Cites] Blood. 1997 May 1;89(9):3354-60 [9129042.001]

[Cites] Sci Total Environ. 1997 Sep 26;204(2):147-60 [9301099.001]

[Cites] Leukemia. 1997 Sep;11(9):1447-52 [9305596.001]

[Cites] Blood. 1998 Jun 1;91(11):4300-10 [9596679.001]

[Cites] J Exp Med. 1999 Apr 5;189(7):1043-52 [10190895.001]

[Cites] Blood. 1999 May 15;93(10):3167-215 [10233871.001]

[Cites] Bone Marrow Transplant. 1999 Aug;24(3):345-8 [10455379.001]

[Cites] Acta Med Scand. 1957 Nov 29;159(3):189-94 [13508085.001]

[Cites] Proc Natl Acad Sci U S A. 2005 May 24;102(21):7653-8 [15894607.001]

[Cites] Blood. 2005 Nov 15;106(10):3658-65 [16076872.001]

[Cites] Ann Oncol. 2006 Jan;17(1):131-4 [16227315.001]

[Cites] Blood. 2006 Apr 1;107(7):2627-32 [16352810.001]

[Cites] Blood. 2006 May 1;107(9):3469-73 [16373661.001]

[Cites] Leukemia. 2006 Aug;20(8):1393-9 [16728984.001]

[Cites] Cancer. 2007 Apr 1;109(7):1355-9 [17326049.001]

[Cites] Blood. 2008 Mar 1;111(5):2505-15 [18299451.001]

(PMID = 19225113.001).

[ISSN] 1091-6490

[Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America

[ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / AQP9 protein, human; 0 / Aquaporins; 0 / Arsenicals; 0 / Oncogene Proteins, Fusion; 0 / Oxides; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide

[Other-IDs] NLM/ PMC2651325

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Arsenic induces clinical remission in patients with acute promyelocytic leukemia and has potential for treatment of other cancers.

MedlinePlus Health Information. consumer health - Melanoma.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Mol Cancer Ther. 2006 Dec;5(12):2963-9 [17172401.001]

[Cites] J Pharmacol Exp Ther. 2005 May;313(2):877-87 [15722406.001]

[Cites] Biochem Pharmacol. 2000 Jan 1;59(1):43-5 [10605933.001]

[Cites] Environ Health Perspect. 2000 May;108(5):393-7 [10811564.001]

[Cites] Biochem Pharmacol. 2000 Sep 15;60(6):771-80 [10930531.001]

[Cites] J Biol Chem. 2000 Nov 17;275(46):36062-6 [10967126.001]

[Cites] Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1643-8 [11172004.001]

[Cites] J Biol Chem. 2001 Apr 6;276(14):11414-9 [11150309.001]

[Cites] Oncologist. 2001;6 Suppl 2:22-8 [11331437.001]

[Cites] Mol Pharmacol. 2001 Aug;60(2):302-9 [11455017.001]

[Cites] EMBO J. 2001 Nov 15;20(22):6371-82 [11707408.001]

[Cites] Biochem Biophys Res Commun. 2002 Mar 8;291(4):861-7 [11866444.001]

[Cites] Toxicol Appl Pharmacol. 2002 Apr 15;180(2):83-91 [11969375.001]

[Cites] Mol Cell Biochem. 2002 May-Jun;234-235(1-2):301-8 [12162448.001]

[Cites] Mol Pharmacol. 2002 Sep;62(3):529-38 [12181429.001]

[Cites] Leuk Lymphoma. 2002 Aug;43(8):1535-40 [12400595.001]

[Cites] Leukemia. 2003 May;17(5):931-40 [12750708.001]

[Cites] Oncogene. 2003 May 19;22(20):3138-51 [12789290.001]

[Cites] Leukemia. 2003 Jul;17(7):1333-7 [12835721.001]

[Cites] Carcinogenesis. 2004 Jan;25(1):21-8 [14514659.001]

[Cites] Cancer Res. 2004 Apr 1;64(7):2502-8 [15059905.001]

[Cites] J Biol Chem. 2004 May 21;279(21):22747-58 [15028728.001]

[Cites] J Biol Chem. 2004 Jul 30;279(31):32700-8 [15161912.001]

[Cites] Int J Cancer. 1977 Dec 15;20(6):869-72 [271143.001]

[Cites] Br J Cancer. 1992 Nov;66(5):888-92 [1419632.001]

[Cites] Biochem J. 1992 Dec 15;288 ( Pt 3):977-82 [1472011.001]

[Cites] Biochem Biophys Res Commun. 1995 Mar 8;208(1):345-52 [7887949.001]

[Cites] Blood. 1997 May 1;89(9):3354-60 [9129042.001]

[Cites] Mutat Res. 1997 Jun;386(3):291-8 [9219566.001]

[Cites] Oncol Res. 1997;9(5):237-48 [9306431.001]

[Cites] Biochem J. 2005 Feb 15;386(Pt 1):1-13 [15521820.001]

[Cites] Oncogene. 2005 Jan 20;24(4):616-26 [15580309.001]

[Cites] Arch Toxicol. 2005 Apr;79(4):183-91 [15526190.001]

[Cites] Br J Cancer. 2005 Jul 25;93(2):216-23 [15999103.001]

[Cites] Cell Cycle. 2005 Oct;4(10):1385-8 [16138009.001]

[Cites] Toxicol Sci. 2006 Jan;89(1):164-72 [16207941.001]

[Cites] Exp Cell Res. 2006 May 1;312(8):1401-17 [16487513.001]

[Cites] J Pharmacol Exp Ther. 2006 Jul;318(1):142-51 [16614167.001]

[Cites] J Biol Chem. 2006 Nov 10;281(45):34113-23 [16973625.001]

[Cites] Curr Opin Cell Biol. 1997 Dec;9(6):807-14 [9425345.001]

[Cites] J Natl Cancer Inst. 1998 Jan 21;90(2):124-33 [9450572.001]

[Cites] Blood. 1998 Sep 1;92(5):1497-504 [9716575.001]

[Cites] Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3706-11 [10097101.001]

[Cites] J Natl Cancer Inst. 1999 May 5;91(9):772-8 [10328107.001]

[Cites] Exp Cell Res. 1999 Jun 15;249(2):413-21 [10366441.001]

[Cites] Gynecol Oncol. 2007 Apr;105(1):66-73 [17234259.001]

(PMID = 18328521.001).

[ISSN] 0041-008X

[Journal-full-title] Toxicology and applied pharmacology

[ISO-abbreviation] Toxicol. Appl. Pharmacol.

[Language] ENG

[Grant] United States / NIEHS NIH HHS / ES / P30 ES014443-01A1; United States / NIEHS NIH HHS / ES / P30 ES014443; United States / NIEHS NIH HHS / ES / ES011314-05S1; United States / NIEHS NIH HHS / ES / ES011314-05; United States / NIEHS NIH HHS / ES / P30ES014443; United States / NIEHS NIH HHS / ES / P30 ES001247; United States / PHS HHS / / R01E S011314; United States / NIEHS NIH HHS / ES / T32ES011564; United States / NIEHS NIH HHS / ES / T32 ES011564; United States / NIEHS NIH HHS / ES / T32 ES011564-03; United States / NIEHS NIH HHS / ES / P30ES001247; United States / NIEHS NIH HHS / ES / ES011564-03; United States / NIEHS NIH HHS / ES / ES013372-03; United States / NIEHS NIH HHS / ES / F30 ES013372-03; United States / NIEHS NIH HHS / ES / R01 ES011314; United States / NIEHS NIH HHS / ES / R01 ES011314-05S1; United States / NIEHS NIH HHS / ES / R01 ES011314-05

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.

[Publication-country] United States

[Chemical-registry-number] 0 / Arsenites; 0 / Sodium Compounds; 48OVY2OC72 / sodium arsenite

[Other-IDs] NLM/ NIHMS54377; NLM/ PMC2474465

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Retinoic acid-induced CD38 antigen promotes leukemia cells attachment and interferon-gamma/interleukin-1beta-dependent apoptosis of endothelial cells: implications in the etiology of retinoic acid syndrome.

All-trans retinoic acid (RA) treatment of patients with acute promyelocytic leukemia (APL) induces complete remission in more than 90% of the cases.

Importantly, RA-induced CD38 expression promoted strong attachment of leukemia cells to endothelial cells, and incubation of endothelial cells with either high concentration (100 ng/ml) of IFN-gamma alone or low concentration of IL-1beta and IFN-gamma (10 ng/ml, each) induced strong apoptotic responses as revealed by caspase-8 activation and DNA fragmentation.

[MeSH-major] Antigens, CD38 / metabolism. Apoptosis / drug effects. Endothelium, Vascular / pathology. Interferon-gamma / pharmacology. Interleukin-1beta / pharmacology. Leukemia, Promyelocytic, Acute / pathology. Tretinoin / pharmacology

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. NITRIC OXIDE .

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16920192.001).

[ISSN] 0145-2126

[Journal-full-title] Leukemia research

[ISO-abbreviation] Leuk. Res.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / CA092115; United States / PHS HHS / / P01 PA 55164

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] England

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interleukin-1beta; 0 / Receptors, Retinoic Acid; 31C4KY9ESH / Nitric Oxide; 5688UTC01R / Tretinoin; 82115-62-6 / Interferon-gamma; EC 3.2.2.5 / Antigens, CD38

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group.

PURPOSE: Several phase II studies have suggested that cytarabine (AraC) was not required in the treatment of newly diagnosed acute promyelocytic leukemia (APL) patients receiving all-trans-retinoic acid (ATRA), an anthracycline, and maintenance therapy, and we aimed at confirming this finding in a randomized trial.

RESULTS: Overall, 328 (96.5%) of 340 patients achieved complete remission (CR).

[MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cytarabine / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy

[MeSH-minor] Adult. Daunorubicin / administration & dosage. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Remission Induction. Survival Analysis. Tretinoin / administration & dosage

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

Hazardous Substances Data Bank. CYTARABINE .

Hazardous Substances Data Bank. DAUNORUBICIN .

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17116939.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; 5688UTC01R / Tretinoin; ZS7284E0ZP / Daunorubicin

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome.

BACKGROUND: Even after the introduction of all-trans retinoic acid (ATRA), early hemorrhagic death remains a major cause of remission induction failure for acute promyelocytic leukemia (APL).

METHODS: To investigate severe hemorrhagic complications during remission induction therapy with respect to incidence, risk factors, and influence on outcome.

Results were analyzed for 279 patients enrolled in the APL97 study conducted by the Japan Adult Leukemia Study Group (JALSG).

Nine of them succumbed to an early death, while the remaining nine patients eventually achieved complete remission (CR).

[MeSH-major] Hemorrhage / etiology. Hemorrhage / pathology. Leukemia, Promyelocytic, Acute / drug therapy. Leukemia, Promyelocytic, Acute / pathology

[MeSH-minor] Adolescent. Adult. Aged. Disease-Free Survival. Female. Humans. Male. Middle Aged. Remission Induction. Risk Factors. Treatment Outcome

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

MedlinePlus Health Information. consumer health - Bleeding.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17241371.001).

[ISSN] 0902-4441

[Journal-full-title] European journal of haematology

[ISO-abbreviation] Eur. J. Haematol.

[Language] eng

[Publication-type] Clinical Trial; Journal Article

[Publication-country] Denmark

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] ASCORBIC ACID - MODULATION OF ARSENIC TRIOXIDE TOXICITY: IMPLICATION FOR THE CLINICAL TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA.

BACKGROUND: Acute Promyelocytic Leukemia (APL) is a subtype of acute leukemia which can affect people of any age.

Recent in vitro and in vivo studies have shown that arsenic trioxide (ATO) can induce clinical remission in de-novo and APL patients that have relapsed from conventional treatment.

AIM: The aim of this research was to study the modulatory effect of AA on ATO-induced oxidative stress in leukemia cells.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 26549974.001).

[ISSN] 1257-2535

[Journal-full-title] Metal ions in biology and medicine : proceedings of the ... International Symposium on Metal Ions in Biology and Medicine held ... = Les ions metalliques en biologie et en medecine : ... Symposium international sur les ions metalliques ...

[ISO-abbreviation] Met Ions Biol Med

[Language] ENG

[Grant] United States / NCRR NIH HHS / RR / G12 RR013459; United States / NCRR NIH HHS / RR / G12 RR013459-010007

[Publication-type] JOURNAL ARTICLE

[Publication-country] France

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Extramedullary infiltration at diagnosis and prognosis in children with acute myelogenous leukemia.

BACKGROUND: Extramedullary infiltration (EMI) is an occasional clinical symptom in childhood acute myelogenous leukemia (AML), but there is considerable controversy regarding the prognostic significance of EMI in AML.

PROCEDURE: We evaluated the frequency and prognostic significance of EMI at diagnosis of AML in children.

RESULTS: Of 240 cases of de novo AML excluding children with Down syndrome and acute promyelocytic leukemia, 56 (23.3%) showed EMI at diagnosis.

The complete remission rate following induction chemotherapy was lower in patients with EMI.

A detailed analysis showed that patients with EMI with a WBC count at diagnosis of over 100 x 10(9)/L or infiltration into the central nervous system are likely to have a poor prognosis.

CONCLUSIONS: CNS leukemia and EMI together with a WBC count of >100 x 10(9)/L at diagnosis of AML are high risk factors for relapse, and alternative treatment approaches for patients with these characteristics should be explored.

[MeSH-major] Leukemia, Myeloid / pathology. Leukemic Infiltration / epidemiology. Sarcoma, Myeloid / epidemiology

[MeSH-minor] Acute Disease. Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone and Bones / pathology. Central Nervous System / pathology. Child. Child, Preschool. Cytarabine / administration & dosage. Disease-Free Survival. Etoposide / administration & dosage. Female. Follow-Up Studies. Gingiva / pathology. Humans. Hydrocortisone / administration & dosage. Idarubicin / administration & dosage. Infant. Infant, Newborn. Japan / epidemiology. Kaplan-Meier Estimate. Male. Methotrexate / administration & dosage. Orbit / pathology. Prognosis. Remission Induction. Skin / pathology. Testis / pathology

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.

Hazardous Substances Data Bank. CYTARABINE .

Hazardous Substances Data Bank. ETOPOSIDE .

Hazardous Substances Data Bank. HYDROCORTISONE .

Hazardous Substances Data Bank. METHOTREXATE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16550530.001).

[ISSN] 1545-5009

[Journal-full-title] Pediatric blood & cancer

[ISO-abbreviation] Pediatr Blood Cancer

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate; ZRP63D75JW / Idarubicin

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocytic leukemia.

We report here a preliminary experience with gemtuzumab ozogamicin (GO) used at low dosage (3 mg/m (2)) in 3 elderly patients with acute promyelocytic leukaemia (APL) who presented molecular relapse and were unfit for intensive chemotherapy.

[MeSH-major] Aminoglycosides / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Leukemia, Promyelocytic, Acute / drug therapy

[MeSH-minor] Aged. Antibodies, Monoclonal, Humanized. Dose-Response Relationship, Drug. Humans. Male. Remission Induction

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17768126.001).

[ISSN] 1592-8721

[Journal-full-title] Haematologica

[ISO-abbreviation] Haematologica

[Language] eng

[Publication-type] Case Reports; Letter

[Publication-country] Italy

[Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / gemtuzumab

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Preferential methylation of Wnt inhibitory factor-1 in acute promyelocytic leukemia: an independent poor prognostic factor.

[MeSH-major] Biomarkers, Tumor / metabolism. Carrier Proteins / metabolism. Leukemia, Promyelocytic, Acute / physiopathology. Repressor Proteins / metabolism

[MeSH-minor] Adaptor Proteins, Signal Transducing. Azacitidine / pharmacology. Cell Line, Tumor. Cell Proliferation / drug effects. Humans. Methylation. Multivariate Analysis. Prognosis. RNA, Messenger / drug effects. RNA, Messenger / metabolism. Recurrence. Remission Induction. Reverse Transcriptase Polymerase Chain Reaction / methods. Risk Factors. Sensitivity and Specificity. Survival Rate. Tretinoin / therapeutic use. Tumor Cells, Cultured

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

Hazardous Substances Data Bank. AZACITIDINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16525492.001).

[ISSN] 0887-6924

[Journal-full-title] Leukemia

[ISO-abbreviation] Leukemia

[Language] eng

[Publication-type] Comparative Study; Letter; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / RNA, Messenger; 0 / Repressor Proteins; 0 / WIF1 protein, human; 5688UTC01R / Tretinoin; M801H13NRU / Azacitidine

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Speciation of arsenic trioxide metabolites in blood cells and plasma of a patient with acute promyelocytic leukemia.

Arsenic trioxide (As(2)O(3)) has been widely accepted as the second-best choice for the treatment of relapsed and refractory acute promyelocytic leukemia (APL) patients.

To clarify the speciation of arsenic, the blood samples were collected at various time points from a patient with APL after remission induction therapy and during consolidation therapy.

[MeSH-major] Arsenicals / blood. Arsenicals / metabolism. Leukemia, Promyelocytic, Acute / blood. Leukemia, Promyelocytic, Acute / metabolism. Oxides / blood. Oxides / metabolism

[MeSH-minor] Chromatography, High Pressure Liquid. Dose-Response Relationship, Drug. Drug Administration Schedule. Humans. Male. Mass Spectrometry. Middle Aged. Recurrence. Remission Induction. Time Factors. Tretinoin / therapeutic use

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19009285.001).

[ISSN] 1618-2650

[Journal-full-title] Analytical and bioanalytical chemistry

[ISO-abbreviation] Anal Bioanal Chem

[Language] eng

[Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Germany

[Chemical-registry-number] 0 / Arsenicals; 0 / Oxides; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Therapy-related myelodysplastic syndrome with monosomy 5 after successful treatment of acute myeloid leukemia (M2).

We describe a patient who developed myelodysplastic syndrome over 2 years after achieving complete remission of acute myeloid leukemia (AML).

The patient was treated in July 1998 with anthracycline, etoposide, and behenoyl cytarabine chemotherapy for AML (French-American-British classification, M2; World Health Organization classification, AML with maturation) and achieved complete remission.

The pancytopenia progressed rapidly, and he died 2 months after the diagnosis of MDS.

Therapy-related MDS and AML (t-MDS/t-AML) developing after treatment for acute leukemia is unusual; the primary leukemia associated with most cases of t-MDS/t-AML is acute promyelocytic leukemia (APL).

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Chromosomes, Human, Pair 5. Cytarabine / analogs & derivatives. Leukemia, Myeloid, Acute / chemically induced. Monosomy. Myelodysplastic Syndromes / chemically induced. Myelodysplastic Syndromes / genetics

Genetic Alliance. consumer health - Leukemia, Myeloid.

Genetic Alliance. consumer health - Myelodysplastic syndromes.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.

Hazardous Substances Data Bank. CYTARABINE .

Hazardous Substances Data Bank. ETOPOSIDE .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15929101.001).

[ISSN] 0361-8609

[Journal-full-title] American journal of hematology

[ISO-abbreviation] Am. J. Hematol.

[Language] eng

[Publication-type] Case Reports; Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Anthracyclines; 0 / Antineoplastic Agents, Phytogenic; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 9YVR68W306 / enocitabine

[Number-of-references] 20

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Long-term remission of extramedullary relapse from acute promyelocytic leukemia after treatment with arsenic trioxide, intrathecal chemotherapy, and brain irradiation.

[MeSH-major] Arsenicals / administration & dosage. Cranial Irradiation. Ear Neoplasms / therapy. Leukemia, Myelomonocytic, Acute. Oxides / administration & dosage. Sarcoma, Myeloid / therapy

[MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Daunorubicin / administration & dosage. Humans. Injections, Spinal. Male. Remission Induction. Tretinoin / administration & dosage

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

Hazardous Substances Data Bank. DAUNORUBICIN .

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17607291.001).

[ISSN] 1543-0790

[Journal-full-title] Clinical advances in hematology & oncology : H&O

[ISO-abbreviation] Clin Adv Hematol Oncol

[Language] eng

[Publication-type] Case Reports; Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Arsenicals; 0 / Oxides; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide; ZS7284E0ZP / Daunorubicin

[Number-of-references] 48

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

BACKGROUND: Myelodysplastic syndromes (MDS), acute erythroleukemia (FAB M6), and acute megakaryocytic leukemia (FAB M7) have overlapping features.

PROCEDURE: Children without Down syndrome or acute promyelocytic leukemia who were newly diagnosed with primary myelodysplastic syndrome or acute myeloid leukemia (AML) M6 or M7 were compared to children with de novo AML M0-M5.

[MeSH-major] Leukemia, Erythroblastic, Acute / diagnosis. Leukemia, Megakaryoblastic, Acute / diagnosis. Myelodysplastic Syndromes / diagnosis

[MeSH-minor] Acute Disease. Child. Child, Preschool. Diagnosis, Differential. Disease-Free Survival. Female. Humans. Male. Prognosis. Remission Induction. Survival Rate. Treatment Outcome

Genetic Alliance. consumer health - Myelodysplastic syndromes.

MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16856158.001).

[ISSN] 1545-5009

[Journal-full-title] Pediatric blood & cancer

[ISO-abbreviation] Pediatr Blood Cancer

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

We describe a case of acute myeloid leukemia (AML) bearing the translocation t(11;17)(q23;q21).

The morphological phenotype represented a monoblastic leukemia, AML French-American-British (FAB) M5a.

Further analysis of the translocation revealed an involvement of the mixed-lineage leukemia (MLL) gene and a region closely proximal to the retinoic acid (RA) receptor alpha (RARA) gene.

In acute promyelocytic leukemia, the translocation (15;17)(q22;q11-21) involving the RARA leads to a maturation arrest that can be overcome by RA, often inducing remission.

[MeSH-major] Antineoplastic Agents / pharmacology. Cell Differentiation / drug effects. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 17 / genetics. Leukemia, Myeloid, Acute / genetics. Translocation, Genetic. Tretinoin / pharmacology

[MeSH-minor] Antigens, CD38 / biosynthesis. Cell Death / drug effects. Cell Death / genetics. Child. Drug Screening Assays, Antitumor. Female. Gene Expression Regulation, Leukemic / drug effects. Gene Expression Regulation, Leukemic / genetics. Hematopoietic Stem Cells / metabolism. Hematopoietic Stem Cells / pathology. Histone-Lysine N-Methyltransferase. Humans. Myeloid-Lymphoid Leukemia Protein / genetics. Myeloid-Lymphoid Leukemia Protein / metabolism. Proto-Oncogene Proteins c-kit / biosynthesis. Receptors, Retinoic Acid / genetics. Receptors, Retinoic Acid / metabolism. Receptors, Retinoic Acid / therapeutic use. Tumor Cells, Cultured

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16044313.001).

[ISSN] 0939-5555

[Journal-full-title] Annals of hematology

[ISO-abbreviation] Ann. Hematol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Germany

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / MLL protein, human; 0 / Receptors, Retinoic Acid; 0 / retinoic acid receptor alpha; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; 5688UTC01R / Tretinoin; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 3.2.2.5 / Antigens, CD38

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Role of all-trans-retinoic acid (ATRA) in the consolidation therapy of acute promyelocytic leukaemia (APL).

The role of all-trans-retinoic acid (ATRA) in the consolidation therapy of acute promyelocytic leukaemia (APL) is undefined at present.

The 5-year overall and leukaemia-free survival of study patients was 82% (95% C.I.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Leukemia, Promyelocytic, Acute / drug therapy. Tretinoin / administration & dosage

[MeSH-minor] Adolescent. Adult. Aged. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Remission Induction. Survival Rate

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15541484.001).

[ISSN] 0145-2126

[Journal-full-title] Leukemia research

[ISO-abbreviation] Leuk. Res.

[Language] eng

[Publication-type] Evaluation Studies; Letter

[Publication-country] England

[Chemical-registry-number] 5688UTC01R / Tretinoin

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Reduced intensity conditioning allogeneic bone marrow transplantation following central nervous system (CNS) relapse of acute promyelocytic leukemia: evidence for a graft-versus-leukemia effect in the CNS.

[MeSH-major] Bone Marrow Transplantation. Central Nervous System Neoplasms / etiology. Graft vs Leukemia Effect. Leukemia, Promyelocytic, Acute / surgery. Transplantation Conditioning / methods

[MeSH-minor] Adult. Humans. Male. Recurrence. Remission Induction. Transplantation, Homologous

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

Genetic Alliance. consumer health - Transplantation.

MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16628719.001).

[ISSN] 0361-8609

[Journal-full-title] American journal of hematology

[ISO-abbreviation] Am. J. Hematol.

[Language] eng

[Publication-type] Case Reports; Letter

[Publication-country] United States

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia.

BACKGROUND: The gene for preferentially expressed antigen of melanoma (PRAME) has been shown to be over-expressed in acute promyelocytic leukemia, but its actual incidence and clinical impact are still unknown.

DESIGN AND METHODS: We studied PRAME expression at diagnosis using real-time quantitative polymerase chain reaction in 125 patients with acute promyelocytic leukemia enrolled in the Spanish PETHEMA-96 (n=45) and PETHEMA-99 (n=80) clinical trials.

In addition, PRAME expression was evaluated as a marker of disease activity in 225 follow-up samples from 67 patients with acute promyelocytic leukemia.

RESULTS: At diagnosis, PRAME expression in patients with acute promyelocytic leukemia was significantly higher (p<0.001) than in patients with non-M3 acute myeloid leukemia (n=213) and in healthy controls (n=10).

Furthermore, patients with acute promyelocytic leukemia with high PRAME expression had a favorable outcome.

Samples at remission showed PRAME levels similar to those in normal controls while samples at relapse over-expressed PRAME again.

CONCLUSIONS: Low PRAME expression defines a subgroup of patients with acute promyelocytic leukemia with a short relapse-free survival.

This marker could be useful as a secondary marker for monitoring patients with acute promyelocytic leukemia.

[MeSH-major] Antigens, Neoplasm / analysis. Leukemia, Promyelocytic, Acute / diagnosis

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18815192.001).

[ISSN] 1592-8721

[Journal-full-title] Haematologica

[ISO-abbreviation] Haematologica

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Italy

[Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / PRAME protein, human

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Successful all-trans retinoic acid treatment of acute promyelocytic leukemia in a patient with NPM/RAR fusion.

Acute promyelocytic leukemia (APL) is characterized by a reciprocal chromosomal translocation involving the gene for retinoic acid receptor alpha(RAR).

Some APL cases also involve rearrangements that fuse RAR to partner genes other than PML, including nucleophosmin (NPM), promyelocytic leukemia zinc finger (PLZF), nuclear mitotic apparatus (NUMA), and Stat5b, but the clinical characteristics of APL without PML-RAR have not been fully clarified.

Complete remission was achieved with ATRA monotherapy and was maintained for 18 months with consolidation chemotherapy.

[MeSH-major] Antineoplastic Agents / administration & dosage. Leukemia, Promyelocytic, Acute / drug therapy. Neoplasm Proteins. Oncogene Proteins, Fusion. Tretinoin / administration & dosage

[MeSH-minor] Chromosomes, Human, Pair 15 / genetics. Chromosomes, Human, Pair 17 / genetics. Humans. Male. Middle Aged. Remission Induction. Renal Dialysis. Translocation, Genetic. Uremia / complications. Uremia / genetics. Uremia / therapy

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Blood. 1996 Feb 1;87(3):882-6 [8562957.001]

[Cites] Am J Hematol. 2003 Oct;74(2):147-8 [14508808.001]

[Cites] Cancer Genet Cytogenet. 2005 Jul 1;160(1):76-8 [15949575.001]

[Cites] Blood. 1995 Feb 15;85(4):1083-94 [7849296.001]

[Cites] Jpn J Hum Genet. 1992 Dec;37(4):293-301 [1297449.001]

[Cites] Nat Genet. 1997 Sep;17 (1):109-13 [9288109.001]

[Cites] EMBO J. 1993 Mar;12(3):1161-7 [8384553.001]

[Cites] Blood. 2000 Apr 15;95(8):2683-90 [10753851.001]

[Cites] Hum Mol Genet. 1999 Sep;8(9):1741-9 [10441338.001]

[Cites] Leukemia. 2001 Sep;15(9):1359-68 [11516096.001]

[Cites] Oncogene. 2001 Oct 29;20(49):7186-203 [11704847.001]

[Cites] Leukemia. 2002 Oct;16(10):1959-73 [12357347.001]

[Cites] Blood. 2000 Aug 15;96(4):1297-308 [10942371.001]

[Cites] Leukemia. 1997 Jul;11(7):1014-6 [9204984.001]

[Cites] Oncogene. 1999 Jan 21;18(3):633-41 [9989813.001]

(PMID = 17988991.001).

[ISSN] 0925-5710

[Journal-full-title] International journal of hematology

[ISO-abbreviation] Int. J. Hematol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Japan

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / NPM-RARalpha protein, human; 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion; 0 / PLZF-RARalpha fusion protein, human; 5688UTC01R / Tretinoin

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Arsenic trioxide treatment in a patient with recurrent acute promyelocytic leukemia (APL)].

Acute promyelocytic leukemia (APL) is a special subtype of acute myeloid leukemia (AML) with M3 morphology and specific chromosomal translocation t(15;17) with resultant leukemogenic PML-RARalpha fusion gene.

Its main characteristics are therapy response using all-trans-retinoic acid (ATRA) and its high rate of recovery; higher than other subtypes of acute myeloid leukemia.

Arsenic trioxide induces a high complete remission rate in patients having an APL relapse.

[MeSH-major] Antineoplastic Agents / therapeutic use. Arsenicals / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Oxides / therapeutic use

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] 2010 Asociación Española de Pediatría. Published by Elsevier Espana. All rights reserved.

(PMID = 20605542.001).

[ISSN] 1695-9531

[Journal-full-title] Anales de pediatría (Barcelona, Spain : 2003)

[ISO-abbreviation] An Pediatr (Barc)

[Language] spa

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Spain

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; S7V92P67HO / arsenic trioxide

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Therapeutic results with apl 93 protocol in acute promyelocytic leukemia (34 cases)].

BACKGROUND: Acute promyelocytic leukaemia (APL) account for approximately 10% to 15% of all AML in most reports.

Clinical features includes the presence in 80% to 90% of patients of a severe hemorrhagic syndrome, a specific balanced translocation between chromosomes 15 and 17 with a fusion of a large pert of the retinoic acid receptor a gene (RARa) on chromosome 17 to a part of the promyelocytic leukaemia (PML) gene on chromosome 15.

AIM: of the study was to assess of the therapeutic management of APL 93 protocol in acute promyelocytic leukemia.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy

[MeSH-minor] Adolescent. Adult. Anthracyclines / administration & dosage. Child. Chromosomes, Human, Pair 15 / genetics. Chromosomes, Human, Pair 17 / genetics. Female. Humans. Male. Middle Aged. Pilot Projects. Receptors, Retinoic Acid. Remission Induction. Retrospective Studies. Survival Analysis. Translocation, Genetic. Tretinoin / administration & dosage. Tunisia

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17294898.001).

[ISSN] 0041-4131

[Journal-full-title] La Tunisie médicale

[ISO-abbreviation] Tunis Med

[Language] fre

[Publication-type] English Abstract; Journal Article; Multicenter Study

[Publication-country] Tunisia

[Chemical-registry-number] 0 / Anthracyclines; 0 / Receptors, Retinoic Acid; 0 / retinoic acid receptor alpha; 5688UTC01R / Tretinoin

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [A successful case of tanshinone II A treatment for relapsed acute promyelocytic leukemia after maintainance therapy of all-trans retinoic acid and arsenic trioxide].

OBJECTIVE: To observe the effects of Tanshinone II A (Tan II A) on acute promyelocytic leukemia (APL) characterized by resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (ATO).

RESULTS: The patient reached morphologically complete remission after using Tan II A intravenously for 54 days.

[MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diterpenes, Abietane / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Neoplasm Recurrence, Local / drug therapy

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

Hazardous Substances Data Bank. MERCAPTOPURINE .

Hazardous Substances Data Bank. METHOTREXATE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 21265116.001).

[ISSN] 1672-173X

[Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition

[ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban

[Language] chi

[Publication-type] Case Reports; English Abstract; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] China

[Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Arsenicals; 0 / Diterpenes, Abietane; 0 / Oxides; 03UUH3J385 / tanshinone; 5688UTC01R / Tretinoin; E7WED276I5 / 6-Mercaptopurine; S7V92P67HO / arsenic trioxide; YL5FZ2Y5U1 / Methotrexate

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Chemotherapy for patients with acute myeloid leukemia in first remission.

Although the majority of patients with acute myeloid leukemia (AML) achieve a complete remission with induction chemotherapy, most will ultimately relapse.

Clinical trials have demonstrated that early intensive consolidation therapy with high-dose cytarabine can produce prolonged responses in up to 40% of patients in remission after standard induction therapy.

Autologous and allogeneic stem cell transplantation in first remission are also valid alternatives, but the value of low-dose maintenance treatment seems confined to acute promyelocytic leukemia.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy

[MeSH-minor] Aged. Clinical Trials as Topic. Combined Modality Therapy. Cytarabine / administration & dosage. Drug Administration Schedule. Hematopoietic Stem Cell Transplantation. Humans. Immunotherapy. Middle Aged. Multicenter Studies as Topic. Remission Induction

Genetic Alliance. consumer health - Leukemia, Myeloid.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

Hazardous Substances Data Bank. CYTARABINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Clin Oncol. 2003 Dec 15;21(24):4496-504 [14673036.001]

[Cites] Blood. 1996 Oct 15;88(8):2841-51 [8874180.001]

[Cites] Blood. 1987 May;69(5):1441-9 [3552076.001]

[Cites] Leukemia. 2003 Nov;17(11):2183-8 [12931210.001]

[Cites] N Engl J Med. 1995 Jan 26;332(4):217-23 [7808487.001]

[Cites] Blood. 1990 Jan 1;75(1):27-32 [2403818.001]

[Cites] Blood. 1993 Jan 15;81(2):311-8 [8422457.001]

[Cites] N Engl J Med. 1998 Dec 3;339(23):1649-56 [9834301.001]

[Cites] Blood. 1991 Nov 15;78(10):2520-6 [1824249.001]

[Cites] Blood. 1997 Jun 15;89(12):4531-6 [9192777.001]

[Cites] Blood. 1997 Oct 15;90(8):2978-86 [9376578.001]

[Cites] N Engl J Med. 1994 Oct 6;331(14):896-903 [8078551.001]

[Cites] Cancer Res. 1998 Sep 15;58(18):4173-9 [9751631.001]

[Cites] Cancer. 1997 Dec 1;80(11 Suppl):2191-8 [9395033.001]

[Cites] Br J Haematol. 2002 Aug;118(2):385-400 [12139722.001]

[Cites] Blood. 2002 Sep 1;100(5):1532-42 [12176867.001]

[Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]

[Cites] Blood. 1992 Apr 15;79(8):1924-30 [1562720.001]

[Cites] J Clin Oncol. 1985 Dec;3(12):1583-9 [3906048.001]

[Cites] Blood. 2005 May 1;105(9):3420-7 [15572587.001]

[Cites] Blood. 1999 Aug 15;94(4):1192-200 [10438706.001]

[Cites] Lancet. 1998 Mar 7;351(9104):700-8 [9504514.001]

[Cites] J Clin Oncol. 2005 Jan 20;23(3):482-93 [15534356.001]

[Cites] Blood. 2005 Jan 15;105(2):481-8 [15213095.001]

[Cites] Blood. 2003 Dec 15;102(13):4277-83 [12933575.001]

[Cites] Leukemia. 1991 Oct;5(10):896-904 [1835746.001]

[Cites] Blood. 1996 Mar 1;87(5):1710-7 [8634416.001]

[Cites] Leukemia. 2005 Jun;19(6):916-20 [15843817.001]

[Cites] Blood. 1984 Apr;63(4):843-7 [6704545.001]

[Cites] J Clin Oncol. 1988 Apr;6(4):583-7 [3282032.001]

(PMID = 20425340.001).

[ISSN] 1558-822X

[Journal-full-title] Current hematologic malignancy reports

[ISO-abbreviation] Curr Hematol Malig Rep

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 04079A1RDZ / Cytarabine

[Number-of-references] 31

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Acute promyelocytic leukemia after whole brain irradiation of primary brain lymphoma in an HIV-infected patient.

The occurrence of acute promyelocytic leukemia (APL) in HIV-infected patients has been reported in only five cases.

Here, we report a case of an HIV-patient who developed APL and upon treatment entered a complete remission.

We treated the patient with antiretroviral therapy and whole-brain irradiation, resulting in complete remission of the lymphoma.

Subsequent cytological and molecular ana?lysis of bone marrow demonstrated complete hematological and molecular remission.

The last follow-up 14 months later, showed sustained molecular APL remission.

In conclusion, we demonstrated that a complete molecular APL remission in an HIV-patient was achieved by using reduced-intensity treatment.

[MeSH-major] Brain / radiation effects. Brain Neoplasms / radiotherapy. HIV Infections / complications. Leukemia, Promyelocytic, Acute / etiology. Leukemia, Radiation-Induced / etiology. Lymphoma / radiotherapy

[MeSH-minor] Adult. Anti-Retroviral Agents / therapeutic use. Antibiotics, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols. Antiretroviral Therapy, Highly Active / methods. Bisexuality. Humans. Idarubicin / therapeutic use. Male. Remission Induction. Tretinoin

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - Brain Tumors.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - Lymphoma.

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Br J Haematol. 2001 Mar;112(4):900-8 [11298584.001]

[Cites] J Clin Oncol. 2003 Jun 1;21(11):2123-37 [12775738.001]

[Cites] Hematology. 2007 Jun;12(3):263-6 [17558705.001]

[Cites] Leuk Lymphoma. 1997 Aug;26(5-6):621-4 [9389370.001]

[Cites] Am J Hematol. 2006 Apr;81(4):300 [16550512.001]

[Cites] Am J Hematol. 2004 Nov;77(3):287-90 [15495246.001]

(PMID = 19258210.001).

[ISSN] 0949-2321

[Journal-full-title] European journal of medical research

[ISO-abbreviation] Eur. J. Med. Res.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Germany

[Chemical-registry-number] 0 / Anti-Retroviral Agents; 0 / Antibiotics, Antineoplastic; 5688UTC01R / Tretinoin; ZRP63D75JW / Idarubicin

[Other-IDs] NLM/ PMC3352204

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A new molecular network comprising PU.1, interferon regulatory factor proteins and miR-342 stimulates ATRA-mediated granulocytic differentiation of acute promyelocytic leukemia cells.

In the acute promyelocytic leukemia (APL) bearing the t(15;17), all-trans-retinoic acid (ATRA) treatment induces granulocytic maturation and complete remission of leukemia.

[MeSH-major] Cell Differentiation. Granulocytes / cytology. Interferon Regulatory Factor-1 / genetics. Interferon-Stimulated Gene Factor 3, gamma Subunit / genetics. Leukemia, Promyelocytic, Acute / genetics. MicroRNAs / genetics. MicroRNAs / physiology. Proto-Oncogene Proteins / genetics. Trans-Activators / genetics. Tretinoin / pharmacology

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19151778.001).

[ISSN] 1476-5551

[Journal-full-title] Leukemia

[ISO-abbreviation] Leukemia

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cell Adhesion Molecules; 0 / EVL protein, human; 0 / IRF1 protein, human; 0 / IRF9 protein, human; 0 / Interferon Regulatory Factor-1; 0 / Interferon-Stimulated Gene Factor 3, gamma Subunit; 0 / MicroRNAs; 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; 0 / Trans-Activators; 0 / proto-oncogene protein Spi-1; 5688UTC01R / Tretinoin

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Rational targeting in acute promyelocytic leukemia.

Acute promyelocytic leukemia (ARL) is characterized by the nearly homogeneous expression of the fusion oncogenic protein PML-RARalpha and the testis-specific cyclin A1 protein, which are implicated in its pathogenesis.

PML-RARalpha binds all-trans retinoic acid with high affinity inducing granulocytic differentiation and remission.

[MeSH-major] Antineoplastic Agents / therapeutic use. Drug Delivery Systems. Leukemia, Promyelocytic, Acute / drug therapy. Tretinoin / therapeutic use

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20133971.001).

[ISSN] 0258-851X

[Journal-full-title] In vivo (Athens, Greece)

[ISO-abbreviation] In Vivo

[Language] eng

[Publication-type] Journal Article

[Publication-country] Greece

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 5688UTC01R / Tretinoin; EC 2.7.11.22 / Cyclin-Dependent Kinases

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Presentation of acute promyelocytic leukemia as granulocytic sarcoma.

This extramedullary tumor can present before, concurrent with or after the diagnosis of acute myeloid leukemia.

GS is extremely uncommon in acute promyelocytic leukemia (APL).

As a proportion of patients never develop systemic disease, correct and timely diagnosis may be rather difficult, but is a prerequisite for optimal outcome.

GS should be considered in the differential diagnosis of children with unusual bone lesions.

[MeSH-major] Diagnostic Errors. Leukemia, Promyelocytic, Acute / complications. Sarcoma, Myeloid / etiology

[MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Arthritis, Psoriatic / diagnosis. Biomarkers, Tumor / analysis. Female. Humans. Oncogene Proteins, Fusion / analysis. Osteolysis / etiology. Osteomyelitis / diagnosis. Remission Induction. Shoulder Pain / etiology. Tretinoin / administration & dosage

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] (c) 2007 Wiley-Liss, Inc.

(PMID = 17437290.001).

[ISSN] 1545-5017

[Journal-full-title] Pediatric blood & cancer

[ISO-abbreviation] Pediatr Blood Cancer

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Oncogene Proteins, Fusion; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; 5688UTC01R / Tretinoin

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] PML-RARalpha inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promyelocytic leukemia.

Acute promyelocytic leukemia (APL) is characterized by generation of the PML-RARalpha fusion gene.

More than 90% of patients with APL achieve a complete remission (CR) with differentiation therapy consisting of ATRA combined with chemotherapy.

[MeSH-major] Antineoplastic Agents / therapeutic use. Arsenicals / therapeutic use. Benzoates / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Oncogene Proteins, Fusion / antagonists & inhibitors. Oxides / therapeutic use. Tetrahydronaphthalenes / therapeutic use. Tretinoin / therapeutic use

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

SciCrunch. DrugBank: Data: Chemical .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cancer Chemother Pharmacol. 2001 Aug;48 Suppl 1:S65-71 [11587370.001]

[Cites] Nat Rev Cancer. 2002 Sep;2(9):705-13 [12209159.001]

[Cites] Cell. 1997 May 2;89(3):373-80 [9150137.001]

[Cites] Nat Rev Cancer. 2001 Dec;1(3):181-93 [11902573.001]

[Cites] Int J Hematol. 2005 Oct;82(3):224-9 [16207595.001]

[Cites] Blood. 1997 Aug 1;90(3):967-73 [9242525.001]

[Cites] J Clin Oncol. 1998 Jan;16(1):78-85 [9440726.001]

[Cites] Ann Intern Med. 2000 Dec 5;133(11):881-5 [11103058.001]

[Cites] Leukemia. 2003 Aug;17(8):1454-63 [12886231.001]

[Cites] Hematology Am Soc Hematol Educ Program. 2006;:156-61, 514 [17124055.001]

[Cites] Blood. 1999 Nov 1;94(9):3015-21 [10556184.001]

[Cites] J Clin Oncol. 2001 Sep 15;19(18):3852-60 [11559723.001]

[Cites] J Biol Chem. 1992 Oct 25;267(30):21486-91 [1328234.001]

[Cites] Oncogene. 2001 Oct 29;20(49):7257-65 [11704854.001]

[Cites] Blood. 2007 Jul 1;110(1):59-66 [17374742.001]

[Cites] Blood. 2002 Jun 1;99(11):4222-4 [12010830.001]

[Cites] Blood. 2005 Dec 1;106(12):3768-76 [16105978.001]

[Cites] J Med Chem. 1988 Nov;31(11):2182-92 [3184125.001]

[Cites] Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5328-35 [15044693.001]

[Cites] Cell. 1991 Aug 23;66(4):663-74 [1652368.001]

[Cites] Blood. 2005 Apr 15;105(8):3019-25 [15604216.001]

[Cites] J Cancer Res Clin Oncol. 1995;121(11):696-8 [7593136.001]

[Cites] Leukemia. 2002 Apr;16(4):617-22 [11960341.001]

[Cites] Nature. 1995 Oct 5;377(6548):454-7 [7566127.001]

[Cites] Blood. 1988 Aug;72(2):567-72 [3165295.001]

[Cites] Blood. 1999 Aug 15;94(4):1192-200 [10438706.001]

[Cites] Blood. 2006 May 1;107(9):3469-73 [16373661.001]

[Cites] Leukemia. 2002 Oct;16(10):1927-32 [12357344.001]

[Cites] Nature. 1989 Jun 29;339(6227):714-7 [2544807.001]

[Cites] Blood. 2002 Nov 1;100(9):3141-6 [12384411.001]

[Cites] Blood. 1993 Sep 1;82(5):1573-7 [8395911.001]

[Cites] Science. 2002 Feb 8;295(5557):1079-82 [11834837.001]

[Cites] Blood. 1999 Jun 15;93(12):4131-43 [10361110.001]

[Cites] Blood. 2000 Aug 15;96(4):1247-53 [10942364.001]

[Cites] Blood. 1997 May 1;89(9):3354-60 [9129042.001]

[Cites] Cancer Chemother Pharmacol. 2007 Mar;59(4):485-93 [16937107.001]

[Cites] Int J Hematol. 2000 Dec;72(4):470-3 [11197214.001]

[Cites] N Engl J Med. 1997 Oct 9;337(15):1021-8 [9321529.001]

[Cites] Arch Biochem Biophys. 1980 Feb;199(2):374-83 [7362233.001]

[Cites] Ann Intern Med. 1996 May 15;124(10):893-6 [8610919.001]

[Cites] Blood. 1996 Jan 15;87(2):725-33 [8555497.001]

[Cites] Blood. 1995 Mar 1;85(5):1202-6 [7858250.001]

[Cites] Hematology Am Soc Hematol Educ Program. 2006;:147-55 [17124054.001]

[Cites] J Natl Cancer Inst. 1998 Nov 4;90(21):1621-5 [9811311.001]

(PMID = 17929112.001).

[ISSN] 1341-9625

[Journal-full-title] International journal of clinical oncology

[ISO-abbreviation] Int. J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] Japan

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Benzoates; 0 / Oncogene Proteins, Fusion; 0 / Oxides; 0 / Tetrahydronaphthalenes; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; 08V52GZ3H9 / tamibarotene; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide

[Number-of-references] 46

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Treatment of acute promyelocytic leukemia (APL) with all-trans retinoic acid and/or arsenic trioxide represents a paradigm in targeted cancer therapy because these drugs cause clinical remission by affecting the stability of the fusion oncoprotein promyelocytic leukemia (PML)/retinoic acid receptor alpha (RARA).

[MeSH-major] Autophagy / drug effects. Autophagy / physiology. Leukemia, Promyelocytic, Acute / drug therapy. Leukemia, Promyelocytic, Acute / metabolism. Nuclear Proteins / metabolism. Oncogene Proteins, Fusion / metabolism. Receptors, Retinoic Acid / metabolism. Transcription Factors / metabolism. Tumor Suppressor Proteins / metabolism

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Blood. 2010 Sep 30;116(13):2200-1 [20884808.001]

(PMID = 20574048.001).

[ISSN] 1528-0020

[Journal-full-title] Blood

[ISO-abbreviation] Blood

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Arsenicals; 0 / Intracellular Signaling Peptides and Proteins; 0 / Nuclear Proteins; 0 / Oncogene Proteins, Fusion; 0 / Oxides; 0 / RNA, Small Interfering; 0 / Receptors, Retinoic Acid; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; 0 / retinoic acid receptor alpha; 143220-95-5 / PML protein, human; 5688UTC01R / Tretinoin; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; S7V92P67HO / arsenic trioxide

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A survival study and prognostic factors analysis on acute promyelocytic leukemia at a single center.

This study was aimed to investigate the factors influencing long-term survival on patients with acute promyelocytic leukemia.

In total, 222 patients, 184 achieved complete remission (CR) with the CR rate of 82.88% and 22 patients died during early induction therapy with the early-death-rate of 10%.

Univariate and multivariate analysis of eight factors potentially influencing survival and prognosis were carried out with Log-Rank and Cox regression method, including sex, age, initial WBC count, the level of lactic dehydrogenase (LDH), first induction regimen, days from induction therapy to CR, post-remission therapy and the status of PML-RAR alpha fusion gene by reverse transcription-polymerase chain reaction (RT-PCR).

Univariate analyses showed that initial WBC count, first induction regimen, days from induction therapy to CR, post-remission therapy regimen and the status of PML-RAR alpha in remission were important prognostic factors for long-term survival.

Multivariate study showed that only post-remission therapy regimen was associated with RFS and OS.

It is concluded that the post-remission treatment combining ATRA, As(2)O(3) and chemotherapy would significantly improve the long-term survival of APL patients achieving CR(1).

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Leukemia, Promyelocytic, Acute / drug therapy. Leukemia, Promyelocytic, Acute / mortality

[MeSH-minor] Adolescent. Adult. Arsenicals / administration & dosage. Child. Child, Preschool. Disease-Free Survival. Follow-Up Studies. Humans. Male. Middle Aged. Oncogene Proteins, Fusion / genetics. Oxides / administration & dosage. Recurrence. Remission Induction. Retrospective Studies. Risk Factors. Survival Rate. Tretinoin / administration & dosage

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17007927.001).

[ISSN] 0145-2126

[Journal-full-title] Leukemia research

[ISO-abbreviation] Leuk. Res.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Arsenicals; 0 / Oncogene Proteins, Fusion; 0 / Oxides; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Immunotherapy for acute myeloid leukemia.

Although the humanized anti-CD33 antibody HuM195 has only modest activity against overt acute myeloid leukemia (AML), it can eliminate minimal residual disease in acute promyelocytic leukemia.

[MeSH-major] Immunotherapy / methods. Leukemia, Myeloid, Acute / therapy

[MeSH-minor] Aminoglycosides / pharmacology. Antibodies, Monoclonal / pharmacology. Antibodies, Monoclonal, Humanized. Antigens, CD / chemistry. Antigens, CD45 / chemistry. Antigens, Differentiation, Myelomonocytic / chemistry. Bismuth / chemistry. Cell Adhesion Molecules / chemistry. Humans. Immunotoxins / chemistry. Radioimmunotherapy. Radioisotopes / chemistry. Recurrence. Remission Induction. Sialic Acid Binding Ig-like Lectin 3. T-Lymphocytes / metabolism

Genetic Alliance. consumer health - Leukemia, Myeloid.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

Hazardous Substances Data Bank. BISMUTH, ELEMENTAL .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Leukemia. 1996 Feb;10(2):321-6 [8637241.001]

[Cites] Int J Hematol. 2003 Jul;78(1):56-61 [12894852.001]

[Cites] Cancer Res. 1983 Jan;43(1):265-72 [6571707.001]

[Cites] Blood. 1998 Jul 15;92(2):589-95 [9657759.001]

[Cites] Bone Marrow Transplant. 2003 Sep;32(6):549-56 [12953125.001]

[Cites] J Clin Oncol. 1991 Mar;9(3):478-90 [1999719.001]

[Cites] Cancer Res. 1994 Aug 15;54(16):4362-70 [8044783.001]

[Cites] Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1802-7 [10677537.001]

[Cites] Leuk Res. 2003 Oct;27(10 ):887-91 [12860007.001]

[Cites] Leuk Lymphoma. 2002 Nov;43(11):2125-31 [12533037.001]

[Cites] Blood. 1996 Oct 1;88(7):2450-7 [8839835.001]

[Cites] Blood. 2002 Jun 1;99(11):4222-4 [12010830.001]

[Cites] J Clin Oncol. 1993 Feb;11(2):294-303 [8426207.001]

[Cites] Cancer. 2001 Jul 15;92(2):406-13 [11466696.001]

[Cites] Blood. 1999 Jun 1;93(11):3678-84 [10339474.001]

[Cites] Leukemia. 2003 Feb;17(2):314-8 [12592328.001]

[Cites] Bone Marrow Transplant. 2002 May;29(10):807-16 [12058230.001]

[Cites] Blood. 2003 Jun 15;101(12 ):5068-75 [12609833.001]

[Cites] Biol Blood Marrow Transplant. 2003 Jun;9(6):364-72 [12813444.001]

[Cites] Clin Cancer Res. 2000 Feb;6(2):372-80 [10690513.001]

[Cites] Blood. 1986 Nov;68(5):1030-5 [3768529.001]

[Cites] Blood. 2002 Aug 15;100(4):1233-9 [12149203.001]

[Cites] Blood. 1994 Apr 1;83(7):1760-8 [8142644.001]

[Cites] Haematologica. 2004 Aug;89(8):950-6 [15339678.001]

[Cites] Cancer Res. 1992 Dec 15;52(24):6761-7 [1458463.001]

[Cites] Science. 2001 Nov 16;294(5546):1537-40 [11711678.001]

[Cites] Blood. 2002 Apr 1;99(7):2310-4 [11895761.001]

[Cites] J Clin Oncol. 2001 Jul 1;19(13):3244-54 [11432892.001]

[Cites] Transplantation. 1992 Nov;54(5):829-33 [1440849.001]

[Cites] Clin Cancer Res. 1995 Oct;1(10):1179-87 [9815910.001]

[Cites] J Cancer Res Clin Oncol. 2005 Jan;131(1):1-13 [15565456.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):1891-5 [12569172.001]

[Cites] Blood. 2003 Dec 15;102(13):4277-83 [12933575.001]

[Cites] Clin Cancer Res. 2002 May;8(5):1004-13 [12006512.001]

[Cites] Clin Cancer Res. 1998 Jun;4(6):1421-8 [9626458.001]

[Cites] Blood. 1999 Aug 15;94(4):1237-47 [10438711.001]

[Cites] Blood. 2002 Jul 1;100(1):318-26 [12070043.001]

[Cites] Blood. 2002 Jul 1;100(1):208-16 [12070029.001]

(PMID = 16091194.001).

[ISSN] 1523-3790

[Journal-full-title] Current oncology reports

[ISO-abbreviation] Curr Oncol Rep

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD33 protein, human; 0 / CD66 antigens; 0 / Cell Adhesion Molecules; 0 / Immunotoxins; 0 / Radioisotopes; 0 / Sialic Acid Binding Ig-like Lectin 3; 93NS566KF7 / gemtuzumab; EC 3.1.3.48 / Antigens, CD45; U015TT5I8H / Bismuth

[Number-of-references] 51

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA Group.

PURPOSE: To analyze the simultaneous combination of all-trans retinoic acid (ATRA) and anthracycline monochemotherapy for children with acute promyelocytic leukemia (APL).

Sixty-one children (92%) achieved complete remission (CR).

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Neoplasm Recurrence, Local / drug therapy

[MeSH-minor] 6-Mercaptopurine / administration & dosage. Adolescent. Anthracyclines / administration & dosage. Child. Child, Preschool. Female. Humans. Idarubicin / administration & dosage. Incidence. Male. Methotrexate / administration & dosage. Prognosis. Remission Induction. Risk Factors. Survival Rate. Tretinoin / administration & dosage

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

Hazardous Substances Data Bank. MERCAPTOPURINE .

Hazardous Substances Data Bank. METHOTREXATE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16234524.001).

[ISSN] 0732-183X

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article; Multicenter Study

[Publication-country] United States

[Chemical-registry-number] 0 / Anthracyclines; 5688UTC01R / Tretinoin; E7WED276I5 / 6-Mercaptopurine; YL5FZ2Y5U1 / Methotrexate; ZRP63D75JW / Idarubicin

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG.

Dose density during early induction has been demonstrated to be one of the prime determinants for treatment efficacy in acute myeloid leukemia (AML).

Of 172 de novo AML patients (excluding acute promyelocytic leukemia), 61% reached a complete remission, 22% a complete remission with incomplete peripheral recovery, 7% had persistent leukemia, 10% died (early death) resulting in an overall response rate of 83%.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cytarabine / therapeutic use. Granulocyte Colony-Stimulating Factor / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Mitoxantrone / therapeutic use. Neutropenia / chemically induced

Genetic Alliance. consumer health - Leukemia, Myeloid.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

Hazardous Substances Data Bank. Filgrastim .

Hazardous Substances Data Bank. CYTARABINE .

Hazardous Substances Data Bank. NOVANTRONE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19131552.001).

[ISSN] 1528-0020

[Journal-full-title] Blood

[ISO-abbreviation] Blood

[Language] eng

[Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Recombinant Proteins; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 3A58010674 / pegfilgrastim; BZ114NVM5P / Mitoxantrone; PVI5M0M1GW / Filgrastim

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] External auditory canal and middle ear relapse of acute promyelocytic leukemia treated with arsenic trioxide: case report and review of the literature.

Extramedullary involvement occurs infrequently in acute promyelocytic leukemia and is said to be more common after treatment with all-trans retinoic acid.

A patient with cytogenetically and molecularly confirmed acute promyelocytic leukemia developed isolated extramedullary relapse in the auditory canal and middle ear 4 years and 9 months after initial diagnosis, while in hematologic and molecular remission, successfully treated with arsenic trioxide alone.

[MeSH-major] Arsenicals / therapeutic use. Ear Canal / pathology. Ear Neoplasms / diagnosis. Ear, Middle / pathology. Leukemia, Promyelocytic, Acute / diagnosis. Neoplasm Recurrence, Local / diagnosis. Oxides / therapeutic use

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20186102.001).

[ISSN] 1536-3678

[Journal-full-title] Journal of pediatric hematology/oncology

[ISO-abbreviation] J. Pediatr. Hematol. Oncol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Arsenicals; 0 / Oxides; S7V92P67HO / arsenic trioxide

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Improved outcome for Chinese children with acute promyelocytic leukemia: a comparison of two protocols.

OBJECTIVE: Acute promyelocytic leukemia (APL) is now highly curable, except in many developing countries.

METHODS: The diagnosis was based on the FAB classification and detection of PML-RAR alpha rearrangement.

The treatment failures were: six patients abandoned treatment (37.5%), two who died of intracranial hemorrhage at diagnosis (6.3%) and sepsis in remission (6.3%) respectively, and two who relapsed (12.5%).

Treatment failures included: one who died of intracranial hemorrhage at diagnosis (7.1%) and one who relapsed (7.1%).

[MeSH-major] Leukemia, Promyelocytic, Acute / drug therapy

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

Hazardous Substances Data Bank. CYTARABINE .

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] (c) 2009 Wiley-Liss, Inc.

[CommentIn] Pediatr Blood Cancer. 2009 Sep;53(3):303-5 [19544375.001]

(PMID = 19422024.001).

[ISSN] 1545-5017

[Journal-full-title] Pediatric blood & cancer

[ISO-abbreviation] Pediatr Blood Cancer

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Anthracyclines; 04079A1RDZ / Cytarabine; 5688UTC01R / Tretinoin

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Treatment of acute promyelocytic leukemia by retinoids.

We review the role of all-trans retinoic acid (ATRA) in the treatment of acute promyelocytic leukemia (APL).

Combination treatment probably also reduces the incidence of initial failures, and complete remission (CR) rates greater than 90% are now regularly reported in large multicenter trials.

[MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Tretinoin / therapeutic use

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17217041.001).

[ISSN] 0070-217X

[Journal-full-title] Current topics in microbiology and immunology

[ISO-abbreviation] Curr. Top. Microbiol. Immunol.

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] Germany

[Chemical-registry-number] 0 / Antineoplastic Agents; 5688UTC01R / Tretinoin

[Number-of-references] 132

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Improved treatment results for childhood acute myeloid leukemia in Taiwan.

To improve treatment results for children with de novo acute myeloid leukemia (AML), we introduced a novel protocol, Taiwan Pediatric Oncology Group-AML-97A, for AML other than acute promyelocytic leukemia (APL), for which modified conventional protocols were used.

Stem cell transplantation was performed in 29 patients in first remission with a similar outcome as chemotherapy alone.

The remission rate in the AML-97A study was 90%, the 5-year survival 51 +/- 5.3% (s.e.) and the 5-year event-free survival 50 +/- 4.8%; for APL, these were 100%, 86 +/- 7.0, and 75 +/- 9.8%.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / therapy. Leukemia, Promyelocytic, Acute / therapy. Stem Cell Transplantation

[MeSH-minor] Adolescent. Child. Child, Preschool. Disease-Free Survival. Female. Follow-Up Studies. Humans. Infant. Infant, Newborn. Male. Remission Induction. Taiwan. Treatment Outcome

Genetic Alliance. consumer health - Acute Myeloid Leukemia, Childhood.

Genetic Alliance. consumer health - Leukemia, Myeloid.

MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16281075.001).

[ISSN] 0887-6924

[Journal-full-title] Leukemia

[ISO-abbreviation] Leukemia

[Language] eng

[Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Promyelocytic sarcoma of the spine: a case report and review of the literature.

It can be present before, concurrently with, or after the diagnosis of acute myeloid leukemia.

MS is extremely uncommon in acute promyelocytic leukemia (APL).

The patient presented with neurologic symptoms due to a paravertebral mass of MS after 7 years of complete remission.

Systemic treatment was also given with combined arsenic trioxide and all-trans retinoic acid and the patient was able to achieve a second prolonged clinical and molecular remission.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cancer. 1991 Nov 15;68(10):2281-3 [1913463.001]

[Cites] Ophthalmology. 1992 Sep;99(9):1463-7 [1407980.001]

[Cites] Haematologia (Budap). 1989;22(3):195-9 [2583600.001]

[Cites] Cancer. 1989 Jun 1;63(11):2192-200 [2785843.001]

[Cites] Cancer. 1987 Jan 1;59(1):94-8 [3466663.001]

[Cites] Cancer. 1981 Sep 15;48(6):1426-37 [7023656.001]

[Cites] Cancer. 1994 Apr 15;73(8):2107-12 [7512442.001]

[Cites] Leuk Lymphoma. 1994 Aug;14(5-6):453-6 [7812204.001]

[Cites] Cancer. 1994 Oct 1;74(7):1882-6 [8082094.001]

[Cites] Am J Clin Pathol. 1993 Sep;100(3):276-84 [8379536.001]

[Cites] Leuk Lymphoma. 1996 Jun;22(1-2):183-6 [8724548.001]

[Cites] Semin Oncol. 1997 Feb;24(1):92-102 [9045308.001]

[Cites] Intern Med. 1997 Jul;36(7):484-6 [9240497.001]

[Cites] Br J Haematol. 1997 Aug;98(2):437-9 [9266945.001]

[Cites] Bone Marrow Transplant. 1997 Oct;20(8):689-90 [9383233.001]

[Cites] Cancer. 1998 Oct 15;83(8):1522-8 [9781945.001]

[Cites] Leuk Lymphoma. 1999 Apr;33(3-4):219-29 [10221502.001]

[Cites] Histopathology. 1999 May;34(5):391-8 [10231412.001]

[Cites] Haematologica. 1999 Jun;84(6):565-6 [10366808.001]

[Cites] Leukemia. 1999 Sep;13(9):1406-8 [10482992.001]

[Cites] Leukemia. 2000 Jun;14(6):1006-13 [10865965.001]

[Cites] Haematologica. 2000 Jul;85(7):758-62 [10897129.001]

[Cites] Eur J Haematol. 2000 Mar;64(3):201-3 [10997887.001]

[Cites] J Clin Oncol. 2000 Oct 1;18(19):3435-7 [11013284.001]

[Cites] J Clin Oncol. 2001 Oct 15;19(20):4023-8 [11600603.001]

[Cites] Cancer. 2002 Mar 15;94(6):1739-46 [11920536.001]

[Cites] Haematologica. 2002 May;87(5):485-9 [12010661.001]

[Cites] Leukemia. 2002 Jun;16(6):1127-30 [12040443.001]

[Cites] Eur J Haematol. 2002 May;68(5):310-3 [12144538.001]

[Cites] Ann Pharmacother. 2002 Dec;36(12):1900-6 [12452754.001]

[Cites] Leuk Lymphoma. 2003 Jan;44(1):189-91 [12691162.001]

[Cites] Ann Oncol. 2003 May;14(5):752-7 [12702530.001]

[Cites] Leukemia. 2003 Jun;17(6):1100-3 [12764375.001]

[Cites] Leukemia. 2003 Jul;17(7):1418-9 [12835735.001]

[Cites] Leukemia. 2003 Aug;17(8):1454-63 [12886231.001]

[Cites] Best Pract Res Clin Haematol. 2003 Sep;16(3):453-61 [12935962.001]

[Cites] Best Pract Res Clin Haematol. 2003 Sep;16(3):521-34 [12935967.001]

[Cites] J Korean Med Sci. 2004 Apr;19(2):311-4 [15082912.001]

[Cites] Leuk Res. 2004 Sep;28(9):991-4 [15234578.001]

[Cites] Acta Med Okayama. 2004 Oct;58(5):251-4 [15666994.001]

[Cites] Leukemia. 2005 Mar;19(3):479-80 [15674358.001]

[Cites] Int J Hematol. 2005 Oct;82(3):224-9 [16207595.001]

[Cites] Leukemia. 2006 Jan;20(1):35-41 [16307026.001]

[Cites] Blood. 2006 May 1;107(9):3469-73 [16373661.001]

[Cites] Ann Hematol. 2006 Oct;85(10):741-2 [16718497.001]

[Cites] Int J Hematol. 2006 May;83(4):337-40 [16757435.001]

[Cites] Acta Haematol. 2007;117(2):106-8 [17135723.001]

[Cites] Leukemia. 2007 Mar;21(3):446-52 [17205057.001]

[Cites] J Neurosurg. 2006 Dec;105(6):912-5 [17405265.001]

[Cites] Pediatr Blood Cancer. 2008 Mar;50(3):657-60 [17437290.001]

[Cites] Ann Transplant. 2007;12(3):33-8 [18290568.001]

[Cites] Blood. 2009 Feb 26;113(9):1875-91 [18812465.001]

[Cites] J BUON. 2008 Oct-Dec;13(4):589-92 [19145688.001]

[Cites] Clin Lab Haematol. 1990;12(1):97-9 [2344722.001]

(PMID = 20339529.001).

[ISSN] 1687-9112

[Journal-full-title] Advances in hematology

[ISO-abbreviation] Adv Hematol

[Language] eng

[Publication-type] Journal Article

[Publication-country] Egypt

[Other-IDs] NLM/ PMC2843861

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis].

BACKGROUND: The studies have demonstrated that arsenic trioxide (ATO) in combination with all-trans retinoic acid (ATRA) takes effects in treatment of acute promyelocytic leukemia (APL) through different underlying mechanisms.

DATA EXTRACTION AND ANALYSIS: Related data concerning complete remission rate, overall survival rate, and disease free survival rate, time to complete remission, relapse rate, mortality and adverse reactions were extracted independently by two reviewers.

Compared with ATO monotherapy, ATO plus ATRA could improve time to complete remission and relapse rate of newly diagnosed APL, but could not improve the complete remission rate, disease free survival rate, mortality and liver dysfunction of relapsed APL patients based on meta-analysis and sensitivity analysis.

Compared with ATRA monotherapy, ATO plus ATRA shortened the time to complete remission, improved the disease free survival rate and relapse rate, but increased the incidence of edema during the treatment.

Compared with chemotherapy with ATO plus ATRA, ATO plus ATRA could improve the complete remission rate, relapse rate, mortality and adverse reactions.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Arsenicals / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Oxides / therapeutic use. Tretinoin / therapeutic use

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19912733.001).

[ISSN] 1672-1977

[Journal-full-title] Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine

[ISO-abbreviation] Zhong Xi Yi Jie He Xue Bao

[Language] chi

[Publication-type] English Abstract; Journal Article; Meta-Analysis; Review

[Publication-country] China

[Chemical-registry-number] 0 / Arsenicals; 0 / Oxides; 5688UTC01R / Tretinoin; S7V92P67HO / arsenic trioxide

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Co-expression of promyelocytic leukemia protein abrogated the repressive effect of Daxx on C/EBPbeta as well as the direct interaction of Daxx and C/EBPbeta, presumably by re-recruiting Daxx to PML-oncogenic domains.

In acute promyelocytic leukemia (APL) cells, C/EBPbeta activity is known to be required for all-trans-retinoic acid-induced cell differentiation and disease remission.

Overall, our data identify Daxx as a new negative regulator of C/EBPbeta and provide first clues for a link between abrogation of Daxx-C/EBPbeta complex formation and APL remission.

[MeSH-minor] Adaptor Proteins, Signal Transducing. Animals. Cell Differentiation. Fibroblasts / metabolism. Gene Expression Regulation. HeLa Cells. Humans. Leukemia, Promyelocytic, Acute / metabolism. Nuclear Proteins. Phosphorylation. Protein Structure, Tertiary. Quail. Tretinoin / metabolism. p300-CBP Transcription Factors / metabolism

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Mol Cell Biol. 2004 Dec;24(24):10529-41 [15572661.001]

[Cites] J Biol Chem. 2004 Nov 12;279(46):48013-23 [15339933.001]

[Cites] Cancer Cell. 2005 Feb;7(2):143-53 [15710327.001]

[Cites] J Immunol. 2006 Apr 15;176(8):4843-51 [16585579.001]

[Cites] Proc Natl Acad Sci U S A. 2005 Nov 22;102(47):16973-8 [16287980.001]

[Cites] J Biol Chem. 2005 Mar 18;280(11):10164-73 [15637079.001]

[Cites] EMBO J. 2006 Sep 6;25(17):3955-65 [16917507.001]

[Cites] Mol Cell. 2006 Nov 3;24(3):341-54 [17081986.001]

[Cites] J Biol Chem. 2007 Jan 12;282(2):956-67 [17110376.001]

[Cites] Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2703-8 [17301242.001]

[Cites] J Mol Biol. 2007 Apr 27;368(2):388-97 [17362989.001]

[Cites] Biochem Soc Trans. 2007 Dec;35(Pt 6):1397-400 [18031230.001]

[Cites] Mol Cell Biol. 2008 Mar;28(6):2102-12 [18195047.001]

[Cites] Oncogene. 2008 Apr 3;27(15):2177-86 [17952115.001]

[Cites] Curr Opin Cell Biol. 2008 Apr;20(2):180-5 [18358708.001]

[Cites] Genes Dev. 2008 Apr 15;22(8):998-1010 [18413714.001]

[Cites] Nat Cell Biol. 2008 May;10(5):547-55 [18408733.001]

[Cites] Nat Cell Biol. 2008 May;10(5):538-46 [18408734.001]

[Cites] Mol Cell Endocrinol. 2008 Jul 16;289(1-2):94-101 [18486321.001]

[Cites] J Biol Chem. 2008 Sep 26;283(39):26357-63 [18647749.001]

[Cites] Mol Cell Biol. 2000 Mar;20(5):1784-96 [10669754.001]

[Cites] J Exp Med. 2000 Feb 21;191(4):631-40 [10684855.001]

[Cites] Oncogene. 2000 Feb 10;19(6):745-53 [10698492.001]

[Cites] Genes Dev. 2000 Aug 1;14(15):1920-32 [10921906.001]

[Cites] Oncogene. 2001 Jan 4;20(1):1-9 [11244500.001]

[Cites] Nat Cell Biol. 2001 Aug;3(8):708-14 [11483955.001]

[Cites] J Biol Chem. 2001 Oct 19;276(42):39103-6 [11495919.001]

[Cites] Br J Haematol. 2001 Nov;115(2):287-97 [11703323.001]

[Cites] Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):207-12 [11756662.001]

[Cites] J Biol Chem. 2002 Mar 29;277(13):11156-64 [11799127.001]

[Cites] J Biol Chem. 2002 Jul 12;277(28):25446-56 [11948183.001]

[Cites] J Cell Sci. 2002 Aug 15;115(Pt 16):3319-30 [12140263.001]

[Cites] J Biol Chem. 2002 Nov 15;277(46):44557-65 [12213825.001]

[Cites] EMBO J. 2003 Feb 17;22(4):882-92 [12574124.001]

[Cites] J Biol Chem. 2003 Mar 14;278(11):9609-19 [12524424.001]

[Cites] Blood Rev. 2003 Jun;17(2):71-97 [12642121.001]

[Cites] J Biol Chem. 2003 May 2;278(18):15958-65 [12595526.001]

[Cites] J Biol Chem. 2003 Aug 29;278(35):33416-21 [12810706.001]

[Cites] Nucleic Acids Res. 2003 Sep 15;31(18):5356-67 [12954772.001]

[Cites] J Biol Chem. 2003 Sep 19;278(38):36959-65 [12857754.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10635-40 [12953102.001]

[Cites] Mol Cell Biol. 2003 Oct;23(20):7108-21 [14517282.001]

[Cites] EMBO J. 2003 Nov 3;22(21):5806-16 [14592978.001]

[Cites] Cancer Res. 2003 Dec 1;63(23):8271-7 [14678985.001]

[Cites] Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4100-5 [15016915.001]

[Cites] Nature. 1990 Oct 11;347(6293):558-61 [2170850.001]

[Cites] Cell. 1991 Aug 23;66(4):663-74 [1652368.001]

[Cites] Cell. 1993 Aug 13;74(3):423-31 [8394219.001]

[Cites] Cell. 1994 Jan 28;76(2):333-43 [8293467.001]

[Cites] Cell. 1994 Jan 28;76(2):345-56 [8293468.001]

[Cites] EMBO J. 1994 Mar 1;13(5):1073-83 [8131741.001]

[Cites] Genes Dev. 1994 Nov 15;8(22):2781-91 [7958933.001]

[Cites] EMBO J. 1996 Jun 3;15(11):2771-80 [8654374.001]

[Cites] Cell. 1997 Jun 27;89(7):1067-76 [9215629.001]

[Cites] Mol Cell Biol. 1997 Nov;17(11):6609-17 [9343424.001]

[Cites] Nature. 1998 Feb 19;391(6669):811-4 [9486654.001]

[Cites] Br J Cancer. 1999 Mar;79(7-8):1240-8 [10098766.001]

[Cites] EMBO J. 1999 Jul 1;18(13):3702-11 [10393185.001]

[Cites] Genes Dev. 1999 Aug 1;13(15):1918-23 [10444590.001]

[Cites] J Cell Biol. 1999 Oct 18;147(2):221-34 [10525530.001]

[Cites] Mol Cell Biol. 2005 Jan;25(1):499-511 [15601869.001]

(PMID = 19690170.001).

[ISSN] 1083-351X

[Journal-full-title] The Journal of biological chemistry

[ISO-abbreviation] J. Biol. Chem.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / CCAAT-Enhancer-Binding Protein-beta; 0 / DAXX protein, human; 0 / Nuclear Proteins; 5688UTC01R / Tretinoin; EC 2.3.1.48 / p300-CBP Transcription Factors

[Other-IDs] NLM/ PMC2781424

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Significance of intracellular arsenic trioxide for therapeutic response in acute promyelocytic leukemia.

Arsenic trioxide (As2O3) is an effective drug for treatment of acute promyelocytic leukemia (APL) and malignant tumors.

Cell lines and cell strains of leukemia and solid cancer cells were treated with different concentrations of As2O3, and the concentrations were compared to apoptosis detected by FITC-annexin V and propidium iodide (PI) double staining.

These results indicate that different leukemia and solid carcinoma cell lines have different intracellular arsenic concentrations, which correlate with different sensitivities to As2O3 in clinical treatment.

Novel techniques by maintaining continuous low but effective arsenic levels inside the target leukemic cells in APL may improve the complete remission rate and overall survival with minimum cost and drug toxicity.

[MeSH-major] Arsenicals / pharmacokinetics. Leukemia, Promyelocytic, Acute / pathology. Oxides / pharmacokinetics

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright 2005 Wiley-Liss, Inc.

(PMID = 15682419.001).

[ISSN] 0361-8609

[Journal-full-title] American journal of hematology

[ISO-abbreviation] Am. J. Hematol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Arsenicals; 0 / Oxides; S7V92P67HO / arsenic trioxide

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Treatment of newly diagnosed patients with acute promyelocytic leukemia with modified spanish treatment protocol.

The results of treatment of acute promyelocytic leukemia, when combination ATRA + chemotherapy is used in induction and maintainance therapy and risk adapted strategy applied in consolidation, improved at present time.

29 (90.6%) patients achieved complete hematologic remission, 2 (6.3 %) molecular relapses were observed, death was observed in 4 patients (12.5%).

Current recommendations for treatment with risk-adapted strategy for patients with newly diagnosed acute promyelocytic leukemia resulted in our patients group to comparable outcome and good compliance like in other published studies.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20353280.001).

[ISSN] 0028-2685

[Journal-full-title] Neoplasma

[ISO-abbreviation] Neoplasma

[Language] eng

[Publication-type] Journal Article

[Publication-country] Slovakia

[Chemical-registry-number] 5688UTC01R / Tretinoin

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma.

Arsenic trioxide (ATO) induces remission in 85% of adults with refractory acute promyelocytic leukemia (APL).

We conducted a phase 1 trial of ATO in children (median age 13 y, range, 2-19) with refractory leukemia.

Patients with APL (n=13) received 0.15 mg/kg per day, and patients with other types of leukemia received 0.15 mg/kg per day (n=2) or 0.2 mg/kg per day (n=4).

[MeSH-major] Antineoplastic Agents / pharmacokinetics. Arsenicals / pharmacokinetics. Leukemia, Promyelocytic, Acute / drug therapy. Lymphoma / drug therapy. Oxides / pharmacokinetics

Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.

MedlinePlus Health Information. consumer health - Lymphoma.

COS Scholar Universe. author profiles.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Blood. 1999 Nov 15;94(10):3315-24 [10552940.001]

[Cites] Leuk Lymphoma. 2004 Dec;45(12):2387-401 [15621751.001]

[Cites] J Clin Oncol. 2000 Jul;18(13):2620-5 [10893295.001]

[Cites] Blood. 2001 Jul 15;98(2):266-71 [11435292.001]

[Cites] J Clin Oncol. 2001 Sep 15;19(18):3852-60 [11559723.001]

[Cites] Eur J Clin Pharmacol. 2002 Nov;58(8):521-6 [12451429.001]

[Cites] J Environ Sci Health A Tox Hazard Subst Environ Eng. 2003 Jan;38(1):165-83 [12635825.001]

[Cites] Cancer. 2003 May 1;97(9):2218-24 [12712474.001]

[Cites] J Biol Chem. 2003 Aug 22;278(34):31998-2004 [12767976.001]

[Cites] J Clin Oncol. 2003 Oct 1;21(19):3609-15 [14512391.001]

[Cites] Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4578-83 [15070760.001]

[Cites] Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5328-35 [15044693.001]

[Cites] Blood. 2004 May 1;103(9):3496-502 [14701702.001]

[Cites] Clin Chem. 1992 Dec;38(12):2479-83 [1458588.001]

[Cites] Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3978-83 [9108090.001]

[Cites] Blood. 1997 May 1;89(9):3345-53 [9129041.001]

[Cites] Blood. 1997 May 1;89(9):3354-60 [9129042.001]

[Cites] J Natl Cancer Inst. 1998 Jan 21;90(2):124-33 [9450572.001]

[Cites] N Engl J Med. 1998 Nov 5;339(19):1341-8 [9801394.001]

[Cites] Cancer Res. 1999 Jul 1;59(13):3053-8 [10397243.001]

[Cites] Blood. 1999 Sep 15;94(6):2102-11 [10477740.001]

[Cites] Blood. 2000 Jan 1;95(1):90-5 [10607690.001]

(PMID = 17959855.001).

[ISSN] 0006-4971

[Journal-full-title] Blood

[ISO-abbreviation] Blood

[Language] eng

[Databank-accession-numbers] ClinicalTrials.gov/ NCT00020111

[Grant] United States / NCI NIH HHS / CA / U01 CA097452; United States / NCI NIH HHS / CA / UM1 CA097452; United States / NCI NIH HHS / CA / CA97452; United States / Intramural NIH HHS / /

[Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; S7V92P67HO / arsenic trioxide

[Other-IDs] NLM/ PMC2200837